{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268875","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.315035+00:00","generated_at":"2026-06-09T00:42:00.269646+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AlloVir Q3 net loss $44.3M ($0.39/sh); cash $213.3M funds trials to H2 2024 data","bullets":["Net loss $44.3M vs $42.1M in Q3 2022; diluted EPS loss $0.39 vs $0.50.","Cash, equivalents and short-term investments $213.3M at Sep 30, down from $233.8M at Dec 31, 2022.","R&D expense $34.2M, up from $30.0M YoY, driven by posoleucel trial costs.","Three Phase 3 posoleucel trials enrolling; topline data expected in H2 2024 for all three.","FY 2023 operating expense guidance $150M-$170M, excluding non-cash items."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268875","json":"https://secwatch.observer/filing/0001193125-23-268875.json","markdown":"https://secwatch.observer/filing/0001193125-23-268875.md","text":"https://secwatch.observer/filing/0001193125-23-268875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523268875/0001193125-23-268875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523268875/d559627d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:42:00.269646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d6206bf609216bdced51d4bbad8187d7336a1dd9","claim":"Kalaris Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income net loss was $44.3 million or $0.39 per share, EPS $0.39 per share.","evidence_excerpt":"On November 2, 2023, AlloVir, Inc. announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523268875/0001193125-23-268875-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"net loss was $44.3 million or $0.39 per share"},{"label":"EPS","value":"$0.39 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}